Our study found that high UCHL1 expression was associated with poor chemosensitivity of HER2+ BC cells, and Kaplan–Meier analysis based on the public dataset showed that patients with high UCHL1 expression, especially in ER+ HER2+ BC, had poorer RFS and DMFS, without any significant correlation with OS. The gene discussed is UCHL1; the disease is breast cancer.